Wedbush Issues Negative Estimate for DAWN Earnings
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) – Research analysts at Wedbush reduced their Q1 2025 EPS estimates for Day One Biopharmaceuticals in a research note issued to investors on Monday, April 21st. Wedbush analyst R. Driscoll now forecasts that the company will earn ($0.45) per share for the quarter, down from their previous […]
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN – Free Report) – Research analysts at Wedbush reduced their Q1 2025 EPS estimates for Day One Biopharmaceuticals in a research note issued to investors on Monday, April 21st. Wedbush analyst R. Driscoll now forecasts that the company will earn ($0.45) per share for the quarter, down from their previous […]
